# First Advantage Corp: financial statements, quarterly

FA · Nasdaq · CIK 1210677 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/fa.md) · [Financials](/companies/fa/financials.md) · [Filings](/companies/fa/filings.md) · [Insiders](/companies/fa/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/fa/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [200](/filings/0000950170-24-125426.md) | [203 d](/filings/0001193125-26-076740.md) | [169](/filings/0000950170-25-066989.md) | [185](/filings/0001193125-25-175442.md) | [199](/filings/0001193125-25-269602.md) | [307 d](/filings/0001193125-26-076740.md) | [355](/filings/0001193125-26-211985.md) | [391](/filings/0001193125-26-338063.md) | [409](/filings/0001193125-25-269602.md) | [420 d](/filings/0001193125-26-076740.md) | [385](/filings/0001193125-26-211985.md) | [449](/filings/0001193125-26-338063.md) |
| Research and development | $m | [13.1](/filings/0000950170-24-125426.md) | [10.9 d](/filings/0001193125-26-076740.md) | [12.5](/filings/0000950170-25-066989.md) | [13.7](/filings/0001193125-25-175442.md) | [12.9](/filings/0001193125-25-269602.md) | [24.8 d](/filings/0001193125-26-076740.md) | [27.2](/filings/0001193125-26-211985.md) | [25.7](/filings/0001193125-26-338063.md) | [25.1](/filings/0001193125-25-269602.md) | [23.9 d](/filings/0001193125-26-076740.md) | [24.6](/filings/0001193125-26-211985.md) | [27.3](/filings/0001193125-26-338063.md) |
| Selling, general and administrative | $m | [30.2](/filings/0000950170-24-125426.md) | [27.9 d](/filings/0001193125-26-076740.md) | [40.7](/filings/0000950170-25-066989.md) | [38.6](/filings/0001193125-25-175442.md) | [46.1](/filings/0001193125-25-269602.md) | [139 d](/filings/0001193125-26-076740.md) | [65.6](/filings/0001193125-26-211985.md) | [57.5](/filings/0001193125-26-338063.md) | [57.5](/filings/0001193125-25-269602.md) | [55.7 d](/filings/0001193125-26-076740.md) | [53.5](/filings/0001193125-26-211985.md) | [57.8](/filings/0001193125-26-338063.md) |
| Operating income | $m | [23.2](/filings/0000950170-24-125426.md) | [29.4 d](/filings/0001193125-26-076740.md) | [(0.7)](/filings/0000950170-25-066989.md) | [9.9](/filings/0001193125-25-175442.md) | [9.1](/filings/0001193125-25-269602.md) | [(80.7) d](/filings/0001193125-26-076740.md) | [7.6](/filings/0001193125-26-211985.md) | [37.7](/filings/0001193125-26-338063.md) | [42.2](/filings/0001193125-25-269602.md) | [44.9 d](/filings/0001193125-26-076740.md) | [33.5](/filings/0001193125-26-211985.md) | [57.0](/filings/0001193125-26-338063.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [4.9](/filings/0000950170-24-125426.md) | [1.7 d](/filings/0001193125-26-076740.md) | [(1.4)](/filings/0000950170-25-066989.md) | [0.7](/filings/0001193125-25-175442.md) | [0.8](/filings/0001193125-25-269602.md) | [(4.4) d](/filings/0001193125-26-076740.md) | [2.2](/filings/0001193125-26-211985.md) | [(7.6)](/filings/0001193125-26-338063.md) | [(0.8)](/filings/0001193125-25-269602.md) | [3.8 d](/filings/0001193125-26-076740.md) | [1.1](/filings/0001193125-26-211985.md) | [8.1](/filings/0001193125-26-338063.md) |
| Net income | $m | [10.8](/filings/0000950170-24-125426.md) | [14.8 d](/filings/0001193125-26-076740.md) | [(2.9)](/filings/0001193125-25-269602.md) | [1.9](/filings/0001193125-25-269602.md) | [(8.9)](/filings/0001193125-25-269602.md) | [(100) d](/filings/0001193125-26-076740.md) | [(41.2)](/filings/0001193125-26-338063.md) | [0.3](/filings/0001193125-26-338063.md) | [2.6](/filings/0001193125-25-269602.md) | [3.5 d](/filings/0001193125-26-076740.md) | [2.2](/filings/0001193125-26-338063.md) | [16.9](/filings/0001193125-26-338063.md) |
| Diluted EPS | $ per share | [0.07](/filings/0000950170-24-125426.md) | not reported | [(0.02)](/filings/0000950170-25-066989.md) | [0.01](/filings/0001193125-25-175442.md) | [(0.06)](/filings/0001193125-25-269602.md) | not reported | [(0.24)](/filings/0001193125-26-211985.md) | [0.00](/filings/0001193125-26-338063.md) | [0.01](/filings/0001193125-25-269602.md) | not reported | [0.01](/filings/0001193125-26-211985.md) | [0.10](/filings/0001193125-26-338063.md) |
| Basic EPS | $ per share | [0.08](/filings/0000950170-24-125426.md) | not reported | [(0.02)](/filings/0000950170-25-066989.md) | [0.01](/filings/0001193125-25-175442.md) | [(0.06)](/filings/0001193125-25-269602.md) | not reported | [(0.24)](/filings/0001193125-26-211985.md) | [0.00](/filings/0001193125-26-338063.md) | [0.01](/filings/0001193125-25-269602.md) | not reported | [0.01](/filings/0001193125-26-211985.md) | [0.10](/filings/0001193125-26-338063.md) |

- Revenue: us-gaap:Revenues
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [165](/filings/0000950170-23-062076.md) | [214](/filings/0000950170-25-029067.md) | [245](/filings/0000950170-24-056995.md) | [270](/filings/0000950170-24-093999.md) | [307](/filings/0000950170-24-125426.md) | [169](/filings/0001193125-26-076740.md) | [172](/filings/0000950170-25-066989.md) | [184](/filings/0001193125-25-175442.md) | [217](/filings/0001193125-25-269602.md) | [240](/filings/0001193125-26-338063.md) | [226](/filings/0001193125-26-211985.md) | [238](/filings/0001193125-26-338063.md) |
| Current assets | $m | [349](/filings/0000950170-23-062076.md) | [374](/filings/0000950170-25-029067.md) | [400](/filings/0000950170-24-056995.md) | [427](/filings/0000950170-24-093999.md) | [467](/filings/0000950170-24-125426.md) | [476](/filings/0001193125-26-076740.md) | [472](/filings/0000950170-25-066989.md) | [503](/filings/0001193125-25-175442.md) | [542](/filings/0001193125-25-269602.md) | [562](/filings/0001193125-26-338063.md) | [539](/filings/0001193125-26-211985.md) | [581](/filings/0001193125-26-338063.md) |
| Total assets | $m | [1,629](/filings/0000950170-23-062076.md) | [1,631](/filings/0000950170-25-029067.md) | [1,632](/filings/0000950170-24-056995.md) | [1,636](/filings/0000950170-24-093999.md) | [1,657](/filings/0000950170-24-125426.md) | [3,923](/filings/0001193125-26-076740.md) | [3,872](/filings/0000950170-25-066989.md) | [3,871](/filings/0001193125-25-175442.md) | [3,856](/filings/0001193125-25-269602.md) | [3,834](/filings/0001193125-26-338063.md) | [3,754](/filings/0001193125-26-211985.md) | [3,747](/filings/0001193125-26-338063.md) |
| Current liabilities | $m | [94.8](/filings/0000950170-23-062076.md) | [85.0](/filings/0000950170-25-029067.md) | [93.2](/filings/0000950170-24-056995.md) | [99.1](/filings/0000950170-24-093999.md) | [121](/filings/0000950170-24-125426.md) | [251](/filings/0001193125-26-076740.md) | [241](/filings/0000950170-25-066989.md) | [253](/filings/0001193125-25-175442.md) | [240](/filings/0001193125-25-269602.md) | [230](/filings/0001193125-26-338063.md) | [203](/filings/0001193125-26-211985.md) | [230](/filings/0001193125-26-338063.md) |
| Total liabilities | $m | [741](/filings/0000950170-23-062076.md) | [724](/filings/0000950170-25-029067.md) | [724](/filings/0000950170-24-056995.md) | [723](/filings/0000950170-24-093999.md) | [736](/filings/0000950170-24-125426.md) | [2,616](/filings/0001193125-26-076740.md) | [2,593](/filings/0000950170-25-066989.md) | [2,572](/filings/0001193125-25-175442.md) | [2,555](/filings/0001193125-25-269602.md) | [2,520](/filings/0001193125-26-338063.md) | [2,460](/filings/0001193125-26-211985.md) | [2,453](/filings/0001193125-26-338063.md) |
| Long-term debt | $m | [558](/filings/0000950170-23-062076.md) | [558](/filings/0000950170-25-029067.md) | [559](/filings/0000950170-24-056995.md) | [559](/filings/0000950170-24-093999.md) | [560](/filings/0000950170-24-125426.md) | [2,121](/filings/0001193125-26-076740.md) | [2,117](/filings/0000950170-25-066989.md) | [2,104](/filings/0001193125-25-175442.md) | [2,103](/filings/0001193125-25-269602.md) | [2,080](/filings/0001193125-26-338063.md) | [2,057](/filings/0001193125-26-211985.md) | [2,034](/filings/0001193125-26-338063.md) |
| Current portion of debt | $m | not reported | [0.0](/filings/0000950170-25-029067.md) | not reported | not reported | not reported | [21.9](/filings/0001193125-26-076740.md) | [21.9](/filings/0000950170-25-066989.md) | [21.9](/filings/0001193125-25-175442.md) | [0.0](/filings/0001193125-25-269602.md) | [0.0](/filings/0001193125-26-076740.md) | not reported | not reported |
| Shareholders' equity | $m | [888](/filings/0000950170-23-062076.md) | [907](/filings/0000950170-25-029067.md) | [908](/filings/0000950170-24-056995.md) | [913](/filings/0000950170-24-093999.md) | [921](/filings/0000950170-24-125426.md) | [1,307](/filings/0001193125-26-076740.md) | [1,279](/filings/0000950170-25-066989.md) | [1,299](/filings/0001193125-25-175442.md) | [1,302](/filings/0001193125-25-269602.md) | [1,314](/filings/0001193125-26-338063.md) | [1,294](/filings/0001193125-26-211985.md) | [1,294](/filings/0001193125-26-338063.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [34.4 d](/filings/0000950170-24-125426.md) | [56.7 d](/filings/0001193125-26-076740.md) | [38.3](/filings/0000950170-25-066989.md) | [32.0 d](/filings/0001193125-25-175442.md) | [43.5 d](/filings/0001193125-25-269602.md) | [(85.7) d](/filings/0001193125-26-076740.md) | [19.5](/filings/0001193125-26-211985.md) | [37.3 d](/filings/0001193125-26-338063.md) | [72.4 d](/filings/0001193125-25-269602.md) | [65.9 d](/filings/0001193125-26-076740.md) | [49.4](/filings/0001193125-26-211985.md) | [73.6 d](/filings/0001193125-26-338063.md) |
| Capital expenditure | $m | [1.1 d](/filings/0000950170-24-125426.md) | [0.3 d](/filings/0001193125-26-076740.md) | [0.3](/filings/0000950170-25-066989.md) | [0.6 d](/filings/0001193125-25-175442.md) | [0.4 d](/filings/0001193125-25-269602.md) | [0.3 d](/filings/0001193125-26-076740.md) | [0.5](/filings/0001193125-26-211985.md) | [1.2 d](/filings/0001193125-26-338063.md) | [1.1 d](/filings/0001193125-25-269602.md) | [3.8 d](/filings/0001193125-26-076740.md) | [2.8](/filings/0001193125-26-211985.md) | [4.7 d](/filings/0001193125-26-338063.md) |
| Share repurchases | $m | [3.6](/filings/0000950170-24-125426.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [19.7](/filings/0001193125-26-338063.md) | [18.9](/filings/0001193125-26-338063.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [152](/filings/0000950170-23-062076.md) | [147](/filings/0000950170-24-056995.md) | [145](/filings/0000950170-24-093999.md) | [145](/filings/0000950170-24-125426.md) | [144](/filings/0000950170-25-066989.md) | [146](/filings/0001193125-25-175442.md) | [144](/filings/0001193125-25-269602.md) | [173](/filings/0001193125-26-211985.md) | [175](/filings/0001193125-26-338063.md) | [176](/filings/0001193125-25-269602.md) | [175](/filings/0001193125-26-211985.md) | [173](/filings/0001193125-26-338063.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 171,753,691 at 2026-07-31, from the cover of the [10-Q filed 2026-08-06](/filings/0001193125-26-338063.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:35 ET. No prices; not investment advice.